Episode Details

Back to Episodes
Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained

Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained

Published 4 weeks, 1 day ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/could-cataract-surgery-give-you-a-glaucoma-drug-that-lasts-for-years-the-bimatoprost-releasing-lens-explained

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained Potentially—but not for everyone, and not as a cure for glaucoma. SpyGlass Pharma’s investigational Bimatoprost Drug Pad–Intraocular Lens System, or BIM-IOL, combines an artificial cataract lens with two small drug-releasing pads. The lens is designed to release bimatoprost, a pressure-lowering medicine, for about three years. The early results are striking: in a randomized trial, roughly 96% to 98% of evaluable patients who received the drug-releasing lens were not using additional pressure-lowering drops at 12 months. A much smaller first-in-human study found that 20 of 21 participants followed for three years remained drop-free. Those results make the idea worth taking seriously. But “drop-free” is not the same as “glaucoma-free,” and the strongest three-year result comes from a small, uncontrolled study—not the larger randomized trial. This article reviews the evidence available as of October 18, 2026, including the latest American Academy of Ophthalmology meeting presentation. The BIM-IOL remains investigational and not approved by the United States Food and Drug Administration. AAO 2026 results coverage () What Is the SpyGlass Bimatoprost Drug Pad–Intraocular Lens? During cataract surgery, the cloudy natural lens is removed and replaced with an intraocular lens. The SpyGlass system uses a monofocal artificial lens with two bimatoprost-containing pads attached near the junction between the lens’s clear center and its supporting arms. The lens and pads are placed inside the eye’s capsular bag, where the natural lens used to sit. The pads are positioned outside the main visual area and are designed to release bimatoprost slowly. Unlike an implant placed in the eye’s drainage angle, the BIM-IOL is intended to leave that angle available for future glaucoma procedures. Adding the pads requires preparation of the lens but is intended to fit within a routine cataract-surgery workflow. Published three-year pilot study () The system is designed to deliver medication for three years. That is a design goal supported by laboratory release testing and early human pressure measurements—not yet proof that every patient will receive three full years of effective treatment. What Did the AAO 2026 Presentation Report? At the American Academy of Ophthalmology annual meeting in New Orleans, held October 9–12, 2026, investigator Fiaz Zaman presented 12-month results from SpyGlass’s randomized Phase 1/2 trial. The trial enrolled people with a cataract and either mild-to-moderate open-angle glaucoma or ocular hypertension. AAO 2026 presentation coverage () Trial groups and pressure results A total of 104 people were randomized: For the full table, please open this article on visualfieldtest.com. All participants stopped their existing pressure-lowering treatment for a washout period before the baseline measurements. The exact group mean washout pressures were not included in the public AAO report I could verify. Dividing the reported pressure reductions by the rounded percentages gives an approximate baseline of about 25–27 mmHg, depending on group and measurement time. These are calculated estimates, not separately published baseline figures. AAO

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us